Clinical monitoring and clinical trial supplies were provided by Bausch & Lomb. The authors thank Howard M. Proskin & Associates, Inc. and Lening Zhang, PhD, of Bausch & Lomb for statistical analysis of the data. Publication was sponsored by Bausch

& Lomb, with editorial assistance provided by Churchill Communications. Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. References 1. Besivance [package insert]. Rochester: Bausch & Lomb Inc (2009). 2. Protzko E, Bowman L, Abelson M, for the AzaSite Clinical Study Group, et al. Phase 3 safety comparisons for 1.0% azithromycin PD0332991 in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol Vis Sci. 2007;48:3425–9.PubMedCrossRef 3. Bowman LM, Si E, Pang J, Archibald R, Friedlaender M. Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin. J Ocul Pharmacol Ther. 2009;25(2):133–9.PubMedCrossRef 4. Akpek EK, Vittitow J, Verhoeven RS, et al. Ocular distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J Ocul Pharmacol Ther. 2009;25(5):433–9.PubMedCrossRef 5. Si EC, Bowman LM, Hosseini K. Pharmacokinetic comparisons of bromfenac in DuraSite and

Xibrom. J Ocul Pharmacol LY2109761 Ther. 2011;27(1):61–6.PubMedCrossRef 6. Haas W, Gearinger LS, Usner DW, et al. Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: selleckchem etiology of bacterial conjunctivitis and antibacterial susceptibility profile. Clin Ophthalmol. 2011;5:1369–79.PubMed 7. Ward KW, Lepage J-F, Driot J-Y. Nonclinical pharmacodynamics, pharmacokinetics,

and safety of BOL-3032243-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J Ocul Pharmcol Ther. 2007;23:243–56.CrossRef 8. Haas W, Pillar CM, Zurenko GE, et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 2009;53:3552–60.PubMedCrossRef 9. Haas W, Pillar Amoxicillin C, Hesje CK, Sanfilippo CM, Morris TW. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae. J Antimicrob Chemother. 2010;65:1441–7.PubMedCrossRef 10. Haas W, Pillar CM, Torres M, Morris TW, Sahm DF. Monitoring antibiotic resistance in ocular microorganisms: Results from the ARMOR 2009 Surveillance Study. Am J Ophthalmol. 2011;152:567–74.PubMedCrossRef 11. Cambau E, Matrat S, Xiao-Su P, et al. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli. J Antimicrob Chemother. 2009;63:443–50.PubMedCrossRef 12. Sanfilippo CM, Hesje C, Haas W, Morris TW.